Johns Hopkins Drug Discovery
page-template,page-template-full_width,page-template-full_width-php,page,page-id-76,page-child,parent-pageid-1802,bridge-core-3.0.5,qi-blocks-1.0.6,qodef-gutenberg--no-touch,qodef-qi--no-touch,qi-addons-for-elementor-1.5.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-29.1,qode-theme-bridge,disabled_footer_bottom,wpb-js-composer js-comp-ver-6.9.0,vc_responsive,elementor-default,elementor-kit-3247,x-shortcodes-v3_0_5


The Johns Hopkins Drug Discovery Program has established an unprecedented academia-industry partnership with Eisai to facilitate a collaborative high throughput screening (HTS) process for various drug programs. Under this agreement, our program develops HTS assays for novel therapeutic targets that are in alignment with Eisai’s interests.  Once validated, the HTS assay is transferred to Eisai to screen its proprietary compound library. Hits form HTS are transferred back to our program for structural optimizations. This collaboration provides our program access to a high-quality small molecule library while it provides Eisai access to novel therapeutic targets identified at Johns Hopkins University. Eisai also holds an option to in-license optimized compounds derived from the HTS hits.  See full article on ThePinkSheets